Rare diseases
Investigational molecules
Locations
Recruiting trials first
5 clinical trials in this condition
FranceFranceFrance
The NetherlandsIn short
Neuromyelitis optica spectrum disorder is a rare autoimmune condition that causes severe inflammation in the central nervous system, primarily targeting the optic nerves, spinal cord, and brainstem. Treatment aims to stop acute attacks, prevent future relapses, and manage symptoms to help people maintain quality of life and minimize lasting disability.
When someone receives a diagnosis of neuromyelitis optica spectrum disorder, often shortened to NMOSD, the focus shifts immediately to managing the condition effectively. This rare disease causes the immune system to mistakenly attack parts of the nervous system, leading to episodes called attacks or relapses that can severely damage the optic nerves and spinal cord. Treatment goals center on controlling these attacks quickly, preventing new ones from happening, and helping patients manage any lasting symptoms that affect their daily lives.
NMOSD is not a condition that can be cured at present, but it can be managed. The main pillars of care involve treating acute attacks when they happen and using long-term preventive therapies to reduce the risk of future episodes. Without proper treatment, many people with NMOSD face a high likelihood of repeated attacks — in fact, about 60% of people may experience another attack within just one year if they receive no preventive treatment. Over time, these repeated episodes can lead to serious and permanent disability, including blindness, paralysis, or the need for mobility aids like walkers.
Treatment decisions depend heavily on whether a person tests positive for a specific antibody called aquaporin-4 immunoglobulin G (AQP4-IgG), which is found in up to 80% of NMOSD cases. This antibody plays a direct role in causing damage to the nervous system. Testing for this antibody is essential because it confirms the diagnosis and helps doctors choose the right treatments. NMOSD was once mistaken for multiple sclerosis, but it is now recognized as a completely different disease that requires different therapies. In fact, some treatments used for MS can actually make NMOSD worse, which is why an accurate diagnosis is so important.
Because NMOSD is relapsing-remitting in about 90% of cases, meaning that people have attacks followed by periods of recovery, the ongoing use of medications to suppress the immune system and prevent relapses is generally necessary. Even a single attack can cause lasting damage, so starting preventive treatment as early as possible is crucial.
When an NMOSD attack occurs, the immediate goal is to reduce inflammation in the nervous system as quickly as possible. The first-line treatment typically involves high-dose corticosteroids, which are powerful anti-inflammatory medications given through a vein (intravenously) for several days. These steroid injections work by dampening the immune response that is causing the inflammation. After the intravenous phase, patients may continue taking steroid tablets, such as prednisolone, for a period of time to help control lingering inflammation.
If steroids alone do not improve symptoms, or if the attack is particularly severe, doctors may recommend plasma exchange, also called plasmapheresis. During this procedure, some of the patient's blood is removed, and the liquid portion (plasma) is separated out and replaced with fresh plasma or a plasma substitute. This helps remove harmful antibodies from the bloodstream that are attacking the nervous system. Plasma exchange is particularly useful when steroid treatment has not been effective.
Another option for treating acute attacks is the use of immunoglobulins, which are antibodies given through a drip into a vein. These can help modulate the immune system and reduce inflammation. The choice of treatment depends on the severity of the attack, how quickly the patient responds, and the availability of therapies.
After an acute attack is managed, the focus shifts to preventing future relapses. Long-term preventive treatment is essential because each attack increases the risk of permanent disability. For many years, doctors have used several immunosuppressant medications that work by reducing the activity of the immune system. These medications have been used "off-label," meaning they were not originally developed specifically for NMOSD but have been shown to be effective through clinical experience and observational studies.
One commonly used medication is azathioprine, also known by the brand name Imuran. Azathioprine suppresses the immune system and helps prevent the formation of harmful antibodies. It is taken as a daily tablet and has been used for many years in NMOSD management.
Another widely used option is mycophenolate mofetil, or CellCept. Like azathioprine, this medication reduces immune system activity and is taken orally. Studies and clinical experience suggest that it can be effective in preventing relapses in people with NMOSD.
Rituximab, sold under the brand name Rituxan, is a biological medication that targets specific immune cells called B cells, which play a role in producing harmful antibodies. Rituximab is given as an infusion into a vein, typically every few months. It has become a mainstay of NMOSD treatment and is widely used even though it was originally developed for other conditions.
All of these immunosuppressive medications carry risks. Because they reduce the immune system's ability to fight infections, people taking these drugs are more susceptible to upper respiratory infections and urinary tract infections. Good hygiene, including regular handwashing, is important to reduce infection risk. There is also a rare but serious risk of developing a brain infection called progressive multifocal leukoencephalopathy (PML), caused by the reactivation of a virus in people whose immune systems are weakened. However, no cases of PML have been reported in NMOSD patients taking these medications, though the risk exists based on their use in other conditions.
Patients on long-term immunosuppressive therapy need regular monitoring, including blood tests to check liver function and blood cell counts. Some medications can affect the liver or reduce the number of certain white blood cells, so ongoing medical supervision is essential.
Even with preventive treatment, many people with NMOSD continue to experience symptoms related to past attacks. These symptoms can include chronic pain, muscle spasms, bladder and bowel problems, and vision difficulties. Doctors often prescribe additional medications to help manage these issues.
For nerve pain, doctors may use medications like amitriptyline or gabapentin, which are antidepressants and anticonvulsants that help reduce pain signals. Muscle spasms and stiffness can be treated with muscle relaxants like baclofen or anticonvulsants like carbamazepine. Bladder problems may be managed with medications such as oxybutynin, and bowel issues often respond to laxatives or other supportive treatments.
Physical therapy, occupational therapy, and rehabilitation services play a vital role in helping people regain strength, improve mobility, and adapt to any lasting disabilities. These therapies can include exercises, assistive devices like canes or walkers, and training in daily living activities.
In recent years, significant advances have been made in understanding the biological mechanisms behind NMOSD, and this has led to the development of new, targeted therapies. Several of these innovative drugs have been tested in rigorous clinical trials and are now approved for use in many parts of the world, offering new hope for people living with this condition.
Four preventive medications have been approved specifically for AQP4-IgG-positive NMOSD based on evidence from Phase III clinical trials, the final and most comprehensive stage of testing that compares the new treatment to a placebo or standard treatment.
Eculizumab is a biological medication that works by blocking part of the immune system called the complement system. The complement system is a group of proteins that normally help fight infections, but in NMOSD, it contributes to nerve damage. By inhibiting a specific protein in this system (called C5), eculizumab prevents the formation of the "attack complex" that damages nerve cells. Clinical trials showed that eculizumab significantly reduced the risk of relapses in people with NMOSD. It is given as an infusion into a vein every two weeks after an initial loading phase.
Ravulizumab is a newer medication similar to eculizumab. It also blocks the complement system by targeting the C5 protein, but it lasts longer in the body, allowing for less frequent dosing — typically every eight weeks. This makes it more convenient for patients. Like eculizumab, ravulizumab was shown in clinical trials to reduce relapse rates effectively.
Inebilizumab is a biological therapy that targets B cells, the immune cells responsible for producing antibodies. Specifically, it targets a protein on B cells called CD19. By removing these cells from circulation, inebilizumab reduces the production of harmful AQP4-IgG antibodies. In clinical trials, inebilizumab was highly effective at preventing relapses and improving patient outcomes. It is given as an infusion into a vein every six months.
Satralizumab is a biological medication that blocks the activity of a protein called interleukin-6 (IL-6), which plays a key role in inflammation. IL-6 is involved in the immune response that damages the nervous system in NMOSD. Satralizumab binds to the IL-6 receptor and prevents IL-6 from triggering inflammation. Clinical trials showed that satralizumab reduced the risk of relapses whether used alone or in combination with other immunosuppressive therapies. Unlike the other approved medications, satralizumab can be given as an injection under the skin, which patients can learn to do at home after proper training. It is administered every two to four weeks.
These four medications represent a major step forward in NMOSD treatment. They are designed specifically to target the mechanisms that cause the disease, rather than broadly suppressing the immune system like older therapies. Clinical trials demonstrated that these drugs significantly reduced the risk of relapses and helped more patients remain relapse-free compared to placebo. However, like all medications, they carry potential side effects.
Clinical trials for NMOSD typically progress through several phases. Phase I trials test a new drug in a small group of people to evaluate safety, determine safe dosage ranges, and identify side effects. Phase II trials involve more participants and focus on whether the drug is effective in treating the condition, while continuing to monitor safety. Phase III trials are large studies that compare the new treatment to a placebo or standard treatment to confirm effectiveness, monitor side effects, and collect information that allows the drug to be used safely.
The clinical trials for eculizumab, ravulizumab, inebilizumab, and satralizumab were international studies involving patients from multiple countries, including the United States, Europe, and Asia. Patients with confirmed AQP4-IgG-positive NMOSD were enrolled and randomly assigned to receive either the study drug or a placebo. The primary goal was to measure how many patients experienced relapses over a period of time, typically 96 weeks (about two years).
Research into NMOSD continues, with scientists exploring new therapeutic targets and treatment strategies. Some areas of investigation include therapies that block the binding of AQP4-IgG antibodies to their target protein, treatments that reduce the activity of certain immune cells called granulocytes, and approaches that protect nerve cells from damage.
Another important area of research involves finding better ways to predict relapses and monitor treatment response. Scientists are studying biomarkers — measurable substances in the blood — that could help doctors identify patients at higher risk of attacks or determine when a treatment is working effectively. For example, levels of a protein called glial fibrillary acidic protein (GFAP) and neurofilament light chain in the blood may help detect relapses early.
Research is also focusing on patients who are AQP4-IgG-negative, meaning they do not have the aquaporin-4 antibody. These patients represent a smaller portion of NMOSD cases and may have different underlying causes. Some may have antibodies against a different protein called myelin oligodendrocyte glycoprotein (MOG), which defines a related but distinct condition. Understanding these differences is important for developing tailored treatments.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
